

Applications of Artificial Intelligence in the Screening of Glaucoma in China

Yue Zhang, Ningli Wang and Hanruo Liu*

Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, China

*Corresponding author: Hanruo Liu, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, China



ARTICLE INFO

Received: 📅 April 09, 2020

Published: 📅 April 24, 2020

Citation: Yue Zhang, Ningli Wang, Hanruo Liu. Applications of Artificial Intelligence in the Screening of Glaucoma in China. Biomed J Sci & Tech Res 27(2)-2020. BJSTR. MS.ID.004476.

ABSTRACT

Glaucoma is a main cause of irreversible blindness, with the difficulty in identifying a large number of undiagnosed patients at early stages. Artificial intelligence (AI) has fostered new breakthroughs in automated screening for glaucoma. Recent years, large amounts of studies have been conducted to employ AI in screening and diagnosis of glaucoma in China, which demonstrates great performance in the procedure. It is expected to revolutionize the current management process of diseases and prevent visual ailments, while practical challenges should also be taken into account.

Keywords: Artificial Intelligence; Glaucoma

Abbreviations: AI: Artificial Intelligence

Introduction

Glaucoma is a main cause of irreversible blindness, which is characterized by structural changes in the optic nerve head, death of retinal ganglion cell and loss of visual acuity, affecting estimated 64.3 million patients aged from 40 to 80 years worldwide [1,2]. Glaucoma meets most of the criteria for screening. First, most cases of chronic glaucoma may be asymptomatic at early stages, and the majority of irreversible loss of vision can be prevented by timely diagnosis and treatment [3]. Next, the screening test (retinal photography) is simple, safe and validated. Last but not least, glaucoma has become an important public health problem. Screening for glaucoma has been recommended by many countries and international community's [4]. Artificial intelligence (AI) has fostered new breakthroughs in automated screening and diagnosis for glaucoma. Implementation of AI in ophthalmic images, including fundus photographs and visual fields, has been proved to be featured by high accuracy, sensitivity, and specificity of over 90% [5]. It is believed that AI may serve as a potential alternative to ophthalmologists and trained human graders in the screening of glaucoma.

In China, the prevalence of glaucoma is about 2.6% in people over 40 years old and increases with age, whose blindness rate is 30% [6]. Different from other countries, Features of vast

population, uneven quality of health care and high proportion of open-angle glaucoma increase the difficulty of screening in China. A considerable amount of research has been conducted to employ AI in the screening of glaucoma. In 2018, Li et al. [7] Developed a deep learning system for detecting glaucomatous optic neuropathy which outperformed ophthalmologists. In 2019, Beijing Tongren Hospital and Beijing Institute of Ophthalmology developed a deep learning algorithm for automatically detecting glaucomatous optic nerve changes in fundus images [8]. It showed the sensitivity of 96.1% and specificity of 97.1% by assessment, and a prediction visualization test was performed to better understand the decision-making process [9]. Moreover, Beijing Tongren Hospital also developed the first screening product for glaucoma in China by cooperating with Tencent Medical Health, with an accuracy rate of more than 95%. This product has been launched on linesince June 2019.

Strengths of these studies are clear. Integrating AI well into glaucoma practices is expected to revolutionize the current management process of diseases and prevent visual ailments, thereby alleviating various social burdens in China. However, several challenges exist in adoption of such systems for clinical translation and utility in glaucoma screening programs. First, there are limitations in present studies, which have been acknowledged

by many researchers. For example, it remains unknown that what the exact mechanism is for AI to evaluate features and make predictions. Moreover, fundus images alone is not a guaranteed sign of glaucoma and the evaluation of glaucomatous optic nerve changes is highly subjective, especially in diagnosing glaucoma in earlier stages. Another limitation is that most systems lack inability to detect other important eye conditions, especially high myopia, which is the most common reason for false-negative and false-positive in both human graders and AI. Thus a more developed and integrated system is necessary to improve screening applications in China.

The second important challenge to use AI is that the application and validation of these advanced methods in the real-world screening setting need additional investigations to bolster its support. In consideration of the non-uniform distribution of population and differences in prevalence around China, it is important to compare the performance of AI in populations of different prevalence of glaucoma. In addition, shooting quality and diagnosis ability are inconsistent even in higher-level hospitals across China, especially in economically underdeveloped regions. It will be the first and immediate barrier to broad implementation of AI applications in China. The third challenge is about how to fit AI well into the health care system, and whether this procedure has cost-effectiveness. At present, most scenes accepting applications are hospitals with relevant backward medical resources and primary care clinics. However, to what extent should an ophthalmologist or optometrist trust the AI outcome? In low-resource settings, like western regions, where professional ophthalmologists are in deep need, what should we suggest the individuals with suspected glaucoma to get further confirmation? A fundamental approach to solve the problem might be to balance the distribution of medical resources around the country.

The fourth challenge is about how to avoid doctor-patient conflicts in primary medical sites. According to the Ministry of Health of the People's Republic of China (China Annual of Sanitation, 2017), over the last twenty years, conflicts between patients, families and doctors have been escalating in China, with growing 22.9% annually. Patients show a lack of trust in professional authorities of primary health care providers, and hesitate to give full control of their bodies to doctors. Accordingly, it is welcomed to integrate AI into the health care system timely and effectively, while the practical challenges should also be taken into account. Further

benefits will inevitably come from the use of AI with digital images and multiple other orthogonal datasets, such as cardiovascular and genomic data, which will enhance the value of data utilization for the health care system.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgment

This research was supported by National Natural Science Fund Projects of China (81700813); Beijing Municipal Administration of Hospitals' Youth Programme (QML20180205); The priming scientific research foundation for the junior researcher in Beijing Tongren Hospital, Capital Medical University (2016-YJJ-ZZL-021); Beijing Tongren Hospital Top Talent Training Program, Medical Synergy Science and Technology Innovation Research (Z181100001918035).

References

- Weinreb RN, Aung T, Medeiros FA (2014) The path physiology and treatment of glaucoma: A review. *JAMA* 311(18): 1901-1911.
- Stevens GA, White RA, Flaxman SR, Price H, Jonas JB, et al. (2013) Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990-2010. *Ophthalmology* 120(12): 2377-2384.
- Heijl A, Bengtsson B, Oskarsdottir SE (2013) Prevalence and severity of undetected manifest glaucoma: results from the early manifest glaucoma trial screening. *Ophthalmology* 120(8): 1541-1545.
- Thomas SM, Jeyaraman MM, Hodge WG, Hutnik C, Costella J, et al. (2014) The effectiveness of teleglaucoma versus in-patient examination for glaucoma screening: A systematic review and meta-analysis. *PLoS One* 9(12): e113779.
- Ting DSW, Pasquale LR, Peng L, Campbell JP, Lee AY, et al. (2019) Artificial intelligence and deep learning in ophthalmology. *Br J Ophthalmol* 103(2): 167-175.
- Liang YB, Friedman DS, Zhou Q, Yang X, Sun LP, et al. (2011) Prevalence of primary open angle glaucoma in a rural adult Chinese population: the Handan eye study. *Invest Ophthalmol Vis Sci* 52(11): 8250-8257.
- Li Z, He Y, Keel S, Meng W, Chang RT, et al. (2018) Efficacy of a Deep Learning System for Detecting Glaucomatous Optic Neuropathy Based on Color Fundus Photographs. *Ophthalmology* 125(8): 1199-1206.
- Li L, Xu M, Liu H, Li Y, Wang X, et al. (2019) A Large-scale Database and a CNN Model for Attention-based Glaucoma Detection. *IEEE TRANSACTIONS ON MEDICAL IMAGING* 1(2):1-11.
- Liu H, Li L, Wormstone IM, Qiao C, Zhang C, et al. (2019) Development and Validation of a Deep Learning System to Detect Glaucomatous Optic Neuropathy Using Fundus Photographs. *JAMA Ophthalmol* 137(12): 1353-1360.

ISSN: 2574-1241

DOI: [10.26717/BJSTR.2020.27.004476](https://doi.org/10.26717/BJSTR.2020.27.004476)

Hanruo Liu. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>